Introduction: Atrial fibrillation (AF) is the most common arrhythmia in patients undergoing hemodialysis (HD), which lowers the quality of life (QoL) and increases the risk of dialysis related complications. The present study aimed to evaluate the effectiveness of AF ablation on the QoL in patients undergoing HD. Methods and Results: Nineteen patients undergoing HD (14 men, age 68±8years, 15 paroxysmal AF) who underwent catheter ablation (CA) of drug-refractory AF were enrolled in the study. The ablation outcomes and procedural complications were evaluated and compared to 1053 consecutive patients without HD who underwent AF ablation. The Kidney Disease Quality of Life Short Form (KDQOL-SF) was assessed to evaluate the QoL of the HD patients at baseline and six months after the ablation. During the follow-up period of 17±13 months after the last procedure, the arrhythmia free rate was similar (HD patients 79% vs. non-HD patients 86%, log-rank p=0.82). There were no life-threatening complications in any patients. The KDQOL-SF of the HD patients six months after the ablation showed an improvement in the physical functioning (54±23 to 68±28, p<0.01), general health perceptions (38±17 to 48±15, p<0.01) and symptoms/problems (75±21 to 84±13, p=0.02) as compared to the baseline. Regarding the intradialytic symptoms, the dyspnea during HD significantly improved after the CA in the HD patients without AF recurrence (35% to 6%, p=0.04), while the atrial tachyarrhythmias and hypotension during HD remained unchanged. Conclusions: CA of AF improves the QoL in patients with chronic hemodialysis.

Introduction: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertrophic cardiomyopathy (HCM) and is associated with renal function deterioration. The protective effects of catheter ablation (CA) of AF on the renal function in HCM patients remains unsolved. Methods: From 2009 to 2020, 169 consecutive patients with HCM and AF (age 70±12, 87 males) were retrospectively evaluated. The estimated glomerular filtration rate (eGFR) was evaluated at the study enrollment or one month before the CA and reevaluated three months and 12 months later. Results: Among the 169 patients, 63 underwent CA of AF (ablation group) and the remaining 106 did not (control group). After propensity score matching, 45 pairs were matched. The baseline eGFR was similar between the two groups (P=0.83). During a mean follow-up period of 34±27 months, sinus rhythm was maintained in 36 (80%) patients after 1.7±0.8 ablation procedures. The eGFR significantly decreased from baseline to three months (P<0.01) and from baseline to one year (P<0.01) in the control group, while the eGFR in the ablation group was maintained both from baseline to three months (P=0.94) and from baseline to one year (P=1.00) after the CA. The change in the eGFR between baseline and 12 months was significantly smaller in the ablation group than control group (P<0.01). After a logistic regression analysis, CA of AF was the independent predictor of an improvement of eGFR (OR: 2.81; 95% CI: 1.08-7.36 P=0.04). Conclusions: CA of AF had a protective effect on the renal function in patients with HCM.